Kornimate/medical-research-clean huggingface dataset:
remote ischaemic preconditioning in childhood cancer

Conditions: Cardiotoxicity

Summary: survival rates of children with cancers have improved significantly in the recent few decades. nonetheless, the side effect of this class of drugs on heart function remains to be an issue of concern. exploration of new strategies to protect the heart in the long term is therefore of paramount importance in children undergoing treatment of cancers. previous cardioprotective interventions hav focused on changing the formulation or rate of administration of anthracyclines but with no observable benefits. while dexrazoxane, an iron chelator, has shown to reduce cardiotoxic outcomes, there remains worries of an association between dexrazoxane use and an increased risk of developing secondary malignancies. recently, the clinical application of remote ischaemic preconditioning (ripc) as a non-invasive and an easily applicable non-pharmacological myocardial protective intervention has gained increasing interest. remote ischaemic preconditioning is the phenomenon in which brief episodes of reversible ischaemia and reperfusion applied to one vascular bed render resistance to ischaemia reperfusion injury of tissues and organs distant away. it can be achieved by repeated 5-minute cycles of inflation and deflation of blood pressure cuff placed over the arm or leg to induce limb ischaemia and reperfusion injury. it is noteworthy that anthracycline cardiotoxicity and myocardial reperfusion injury occur through similar pathways. hence, the investigators hypothesize that ripc may reduce myocardial injury in children receiving anthracycline chemotherapy for childhood malignancies. the proposed study aims to conduct a parallel-group blinded randomized controlled trial study to investigate whether ripc may reduce heart damage in childhood cancer patients undergoing anthracycline-based treatment, and to determine the effect of ripc on the changes in levels of cardiac troponin t, and on the occurrence of clinical cardiovascular events and echocardiographic indices.

remote ischemic preconditioning (ripc) protocol will be induced at baseline and before each dose of anthracycline cardiac surgery and once before induction of anesthesia by 3 cycles of 5-min upper or lower limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to 15 mmhg above the systolic blood pressure for 5 minutes followed by 5 minutes of cuff deflation to 0 mmhg.

Eligibility criteria:
inclusion criteria: * patients aged 4 to 18 years old * newly diagnosed patients with solid tumours or haematological malignancies referred for anthracycline-based chemotherapy * no history of being treated with anthracycline-based regimens in the past. exclusion criteria: * existence of congenital or acquired heart disease * presence of syndromal disorders * abnormal baseline echocardiographic assessment * peripheral vascular disease that renders ripc impossible * a platelet count \<30,000/µl.

Keywords: remote ischaemic preconditioning childhood cancer cardio-oncology anthracycline myocardial reperfusion injury
delipid extracorporeal lipoprotein filter from plasma (delp) for acute hemorrhagic stroke

Conditions: Hemorrhagic Stroke

Summary: delipid extracorporeal lipoprotein filter from plasma (delp) has been found to improve neurological function and life ability of ais patients and approved for the treatment of ais by china food and drug administration (cfda). a recent study imply that the neuroprotective effect of delp involved multiple neuroprotective mechanism such as anti-inflammation, free radical scavenging, and decreasing mmp-9. based on the multiple mechanisms, the investigator argues that delp may exert neuroprotective effect on acute cerebral hemorrhage (ach). in this context, the prospective, random, open-label, blind-endpoint, multi-centre study is designed.


Eligibility criteria:
inclusion criteria: * age: 18-80; * spontaneous cerebral hemorrhage; * deep supratentorial intracerebral hemorrhage (basal ganglia) with hematoma volume 5-40ml, or supratentorial lobar hemorrhages with hematoma volume 5-30ml; * nihss: 6-20; * time from onset to delp: 6-48 hours; * premorbid mrs 0 or 1; * signed informed consent; exclusion criteria: * secondary cerebral hemorrhage (secondary to trauma, tumor, vascular malformation, hemorrhage transformation of ischemic stroke, etc.); * comatose patients on admission (gcs score 3-8 on the glasgow coma scale); * patients with intracerebral hemorrhage ruptured into the ventricle, which should be treated by surgery; * planed surgery; * severe hepatic or renal dysfunction, increase in alt or ast (more than 2 times of upper limit of normal value), increase in serum creatinine (more than 1.5 times of upper limit of normal value) or requiring dialysis; * severe hypertension (systolic blood pressure over 200mmhg or diastolic blood pressure over 110 mmhg), or hypotension (systolic blood pressure below 90mmhg or diastolic blood pressure below 60 mmhg); * previous allergy to heparin or calcium; * life expectancy is less than 6 months due to comorbidity * infected at the venipuncture site * hypoproteinemia; * unsuitable for this clinical studies assessed by researcher.
skeletal muscle effects of gh in boys

Conditions: Growth Hormone Deficiency; Idiopathic Short Stature

Summary: the purpose of the study is to measure the functional effects of recombinant gh in skeletal muscle, in addition to growth promotion, in short prepubertal boys with either growth hormone deficiency or idiopathic short stature. patients will be similarly short. the investigators will also compare these values in the short stature cohort to those obtained in testing performed in normally growing age-matched healthy control boys not on gh. the group on gh will be studied before and after 6 and 12 months of gh treatment.

prepubertal boys with significant short stature (height sds ≤-2.0) diagnosed with either gh deficiency or idiopathic short stature (iss) who are identified as candidates for gh treatment will recruited. subjects will have a battery of studies to assess skeletal muscle strength, agility, power and endurance, as well as assessment of body composition and energy expenditure before and after gh administration. gh (somatropin) treatment at standard doses will be given as daily injections at bedtime. subjects will be followed at three-month intervals per the clinical routine, when anthropometric measurements will be obtained. baseline studies will be repeated at 6 and 12 months from initiation of treatment, each patient will serve as his own control pre and post gh. a group of normally statured healthy boys will have the same testing as the study patients but without gh treatment to assess the impact of natural growth on the muscle measures above.

Eligibility criteria:
inclusion criteria: short stature group 1. 30 boys between 6-11 years of age 2. prepubertal 3. short stature (height ≤ -2sds) due to either gh deficiency or idiopathic 4. stable treatment of other pituitary hormone deficiencies 5. naïve to gh therapy, or gh discontinued at least 6 months prior to study normal stature group 1. 15 boys between 6-11 years of age 2. prepubertal 3. normal height (10th to 90th%) exclusion criteria: 1. actively growing brain tumors 2. chronic medical conditions that could affect study outcomes 3. long-term steroid use 4. intense regular physical training programs or organized team sports

Keywords: gh muscle strength prepubertal boys short stature gh treatment muscle agility
effective dose of etanercept in patients treated for juvenile idiopathic arthritis

Conditions: Juvenile Idiopathic Arthritis

Summary: the purpose of this study is to determine the optimal dosage of etanercept in patients treated for idiopathic juvenile arthritis

etanercept, a fully human soluble tumor necrosis factor (tnf) receptor fusion protein, has been demonstrated to be safe and efficacious for the treatment of patients with polyarticular jia. however, many patients experience primary or secondary response failure, suggesting that individualization of treatment regimens may be beneficial. it has been shown that the clinical response to two anti-tnfalpha biological agents (infliximab, adalimumab) closely follows the trough drug levels and the presence of antibodies directed against the drugs. this study was undertaken to investigate whether serologic monitoring of etanercept bioavailability and immunogenicity in individual patients with jia would be useful in optimizing treatment regimens to improve efficacy and tolerability

Eligibility criteria:
inclusion criteria: * patient with juvenile idiopathic arthritis * age \ 4 years (which corresponds to the pediatric amm) * patient on etanercept treatment in the context of his usual care, whatever the dose (but the dose should remain stable in the weight during the study period). the patient must have received at least one injection of etanercept before participating in the study. * signature of consent by the guardians of the child * patient affiliate or entitled to a social security scheme exclusion criteria: * infection progressive * pregnancy and lactation. for adolescents of reproductive age and sexually active, contraception should be used during the duration of treatment with etanercept * contraindication to treatment with etanercept * refusal of the study

Keywords: juvenile idiopathic arthritis etanercept
accuracy of sopro-life camera in comparison with icdas ii for detection of initial caries

Conditions: Caries, Dental

Summary: this study will be conducted to assess diagnostic predictive values of a light induced fluorescence intraoral camera versus those of the visual-tactile assessment method according to modified icdas-ii criteria in clinical

volunteers patients will be assigned in this study. each patient should have at least one posterior tooth with pits and fissure discoloration and maximum 4 teeth. the teeth will be evaluated by two diagnostic methods (d), where d1 represents visual-tactile assessment method (icdas-ii) and d2 represents light induced fluorescence intraoral camera.three operators, the researcher and the 2 supervisors, from the conservative dentistry department, faculty of dentistry, cairo university, will be the examiners in this study. each examiner will record the dental findings using both the visual- tactile assessment method and the fluorescent-aided identification method. the visual-tactile assessment method includes the use of mirror, probe under good illumination condition, while the fluorescent-aided identification method will be performed by light induced fluorescence intraoral camera.

Eligibility criteria:
inclusion criteria: * patients aged from 15 to 50 years. * no gender restriction. * patients should have an acceptable oral hygiene level. * patients must have at least one posterior with fissure discoloration exclusion criteria: * • patients with a compromised medical history. * severe or active periodontal disease. * heavy bruxism or a traumatic occlusion. * acute or chronic dental infection. * pregnant or breastfeeding women. * patients with posterior restorations on molars or premolars.
a study of subjects with previously untreated extensive-stage small-cell lung cancer (sclc) treated with platinum plus etoposide chemotherapy with or without darbepoetin alfa

Conditions: Small Cell Lung Cancer

Summary: the purpose of this study is to evaluate whether increasing or maintaining hemoglobin concentrations with darbepoetin alfa, when administered with platinum-containing chemotherapy in subjects with previously untreated extensive-stage small cell lung cancer (sclc), increases survival.


Eligibility criteria:
inclusion criteria: * pathologically proven sclc, extensive-stage * planned to receive chemotherapy of carboplatin or cisplatin plus etoposide every 3 weeks for 6 cycles * eastern cooperative oncology group (ecog) performance status of 0 to 2 * life expectancy greater than or equal to 3 months * hemoglobin concentration greater than or equal to 9.0 g/dl and less than or equal to 13g/dl * adequate renal, liver and hematopoietic function * subjects must sign and date a written institutional review board /independent ethics committee-approved informed consent form exclusion criteria: * known primary hematologic disorder which could cause anemia * brain metastases that are either symptomatic or treated with medications * unstable or uncontrolled disease/condition, related to or affecting cardiac function * other known primary malignancy within the past 5 years with the exception of curatively treated basal cell carcinoma, squamous cell carcinoma in situ cervical carcinoma or surgically cured malignancies * iron deficiency * known positive test for human immunodeficiency virus infection * received greater than 2 units of packed red blood cells within 4 weeks of randomization or any rbc transfusions within 2 weeks before randomization * received rhuepo or darbepoetin alfa therapy within 4 weeks of randomization * previous chemotherapy for sclc * previous radiotherapy except as symptom palliation for bone or brain lesions and at least 24 hours since prior radiotherapy for symptom palliation providing extent of radiotherapy makes marked bone marrow suppression unlikely * less than 30 days since receipt of any drug or device that is not approved for any indication * pregnant or breast-feeding * not using adequate contraceptive precautions * previously randomized into this study * known hypersensitivity to recombinant mammalian-derived product or any other ingredients contained in the study drug * any medical, mental, or other conditions that makes the subject unsuitable for participation

Keywords: oncology clinical trial hemoglobin darbepoetin alfa survival carboplatin cisplatin etoposide extensive stage small cell lung cancer
kinesiotaping the hand in cerebral palsy

Conditions: Spasticity

Summary: backrounds: thumb in palm deformity restricts hand function by prevent somatosensory input in the children with cerebral palsy who have spasticity in their hands. objecti̇ves: to investigate the effects of thenar palmar kinesiotape application with and without pressure on hand function in children with cerebral palsy. method: 45 children were randomly allocated to one of the thenar taping groups either with or without pressure or to the control group. nine hole peg test and nine parts puzzle test were used to measure hand function. the two study groups were evaluated initially, with taping 20 minutes later and 20 minutes after taping was removed.

backrounds: thumb in palm deformity restricts hand function by prevent somatosensory input in the children with cerebral palsy who have spasticity in their hands. objecti̇ves: to investigate the effects of thenar palmar kinesiotape application with and without pressure on upper extremity function in children with cerebral palsy. method: 45 children were randomly allocated to one of the thenar taping groups either with or without pressure or to the control group. nine hole peg test and nine parts puzzle test were used to measure upper extremity function. the two study groups were evaluated initially, with taping 20 minutes later and 20 minutes after taping was removed.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of cerebral palsy * stable clinical status * hand and/ or wrist spasticity * no passive movement limitation * receiving regular neurodevelopmental rehabilitation * sufficient cognitive level exclusion criteria: * surgery of the upper extremity * orthotic treatment * sensory deficit

Keywords: spasticity, hand function, cerebral palsy, kinesiotape
comprehensive ambulatory antibiotics for the treatment of congenital syphilis

Conditions: Syphilis, Congenital

Summary: cares-1 is a randomised, open-label, phase ii pharmacokinetic (pk) and safety study of ambulatory antibiotics for the treatment of neonates with "all-risk" asymptomatic congenital syphilis.


Eligibility criteria:
inclusion criteria: 1. infants at risk of congenital syphilis at birth defined as: 1. an infant born to a mother who tests positive for syphilis in pregnancy using registered and licensed locally-available diagnostic tests for example but not limited to a treponemal rapid poct, an rpr or both. and 2. the mother is untreated in the current pregnancy defined as: i. she tested positive at antenatal care and received no treatment or ii. she was never tested during antenatal care or iii. she tested negative at antenatal care and positive on re-testing at delivery or c. the mother is inadequately treated in the current pregnancy defined as: i. having received a non-penicillin based treatment regimen; and/or ii. does not have documentation of 3 doses of im benzathine penicillin, given 7-10 days apart, with the last dose given \> 30 days prior to delivery or b. the mother was adequately treated in the current pregnancy but considers herself at risk of re-infection following a midwife delivered explanation of risk (partner treatment, multiple partners etc). 2. infants who are asymptomatic for a diagnosis of congenital syphilis following application of a clinical proforma by the study team (appendix 1) 3. infants who are less than \<= 7 days of life and with a post-menstrual age (pma) of 34-42 weeks (appendix 2). 4. infants who are tolerating enteral feeds, including if they are being administered by an ng tube. exclusion criteria: - 1. the infant's clinical condition at birth or prior to randomisation requires ongoing (\> 48 hours) treatment with antibiotics with the potential for anti-treponemal activity i.e. b-lactams, cephalosporins, carbapenems. 2. they have a birthweight \<2kg 3. they are nil by mouth. 4. they have a life-limiting congenital anomaly
individual structured therapy in early premature infants at the neonatal intensive care unit

Conditions: Infant Development; Neonatal Intensive Care Unit; INDIVIDUALIZED THERAPY

Summary: in this study, investigators aimed to apply an individual structured therapy protocol within the framework of neurodevelopmental therapy principles in early premature infants hospitalized in the neonatal intensive care unit and to examine its effect on the motor development of infants.

the study is planned to include 20 early premature (\<34 weeks) newborns hospitalised in the neonatal intensive care unit. the babies will be divided into two groups as therapy group and control group. internet-based randomisation system will be used to determine the groups according to their risk levels. the risk levels will be determined according to the guidelines of the turkish neonatology association. sterile gowns, masks and bonnets will be used during assessment and therapy to reduce the risk of infection in terms of the safety of the babies, and small lids will be opened so that the physiotherapist's hand can enter to maintain the temperature and oxygen balance in the incubator. therapy group: in addition to routine care, they will be arranged according to the needs of the baby in the form of positioning, hand contacts, passive and active movement of the arms and legs for the development of movement, sensory stimuli around the mouth for oral motor organisation. neurodevelopmental-based application will be applied three days a week, once a day for 10-15 minutes, from the 34th week until 37th week when vital signs are stable. control group: they will be monitored by performing routine care and positioning.

Eligibility criteria:
inclusion criteria 1. hospitalised in the neonatal intensive care unit, 2. born before 34 weeks of gestation 3. medium and low-risk babies 4. newborns who were approved by their families to participate in the study exclusion criteria 1. diagnosed neurological, neuromuscular or genetic disease 2. congenital anomalies 3. newborns whose parents did not consent to participate in the study

Keywords: individualized therapy, infant development, neonatal intensive care unit, early preterm
expanded access program using uromune for patients with recurrent urinary tract infections (ruti)

Conditions: Urinary Tract Infections; Chronic Urinary Tract Infection; Recurrent Urinary Tract Infection; Urinary Tract Infection Bacterial; Bladder Infection

Summary: an expanded access program for uromune® for patients suffering from recurrent/chronic urinary tract infections of diverse etiology. this is for individuals for whom antibiotic therapy has failed, but of consideration in all cases, taking into account antibiotic-induced adverse reactions and increasing antibiotic resistance.

uromune® is a mucosal immunotherapy indicated for the prevention of urinary tract infections caused by different pathogens. it works by stimulating the immune system, thus increasing the resistance against recurrent infections. the active substances are 4 inactivated and selected bacterial strains: * klebsiella pneumoniae 25% * escherichia coli 25% * enterococcus faecalis 25% * proteus vulgaris 25%

Eligibility criteria:
inclusion criteria: * patients suffering recurrent urinary tract infections of diverse etiology. exclusion criteria: * individuals being allergic to any of the ingredients of uromune®. * pregnancy and breast feeding. there are neither specific studies nor a formal contraindication, the physician should value benefits/risk.